243 related articles for article (PubMed ID: 24440112)
21. Repeat revaccination with 23-valent pneumococcal polysaccharide vaccine among adults aged 55-74 years living in Alaska: no evidence of hyporesponsiveness.
Hammitt LL; Bulkow LR; Singleton RJ; Nuorti JP; Hummel KB; Miernyk KM; Zanis C; Whaley M; Romero-Steiner S; Butler JC; Rudolph K; Hennessy TW
Vaccine; 2011 Mar; 29(12):2287-95. PubMed ID: 21255685
[TBL] [Abstract][Full Text] [Related]
22. A 5-year longitudinal follow-up study of serological responses to 23-valent pneumococcal polysaccharide vaccination among patients with HIV infection who received highly active antiretroviral therapy.
Hung CC; Chang SY; Su CT; Chen YY; Chang SF; Yang CY; Liu WC; Wu CH; Chang SC
HIV Med; 2010 Jan; 11(1):54-63. PubMed ID: 19659943
[TBL] [Abstract][Full Text] [Related]
23. Impact of vaccination with seven-valent pneumococcal conjugate vaccine on virologic and immunologic outcomes among HIV-infected adult patients in the era of highly active antiretroviral therapy.
Lu CL; Chang SY; Sun HY; Liu WC; Tseng YT; Hsieh CY; Wu CH; Hung CC; Chang SC
J Formos Med Assoc; 2012 Aug; 111(8):445-51. PubMed ID: 22939663
[TBL] [Abstract][Full Text] [Related]
24. Heptavalent pneumococcal conjugate vaccine elicits similar antibody response as standard 23-valent polysaccharide vaccine in adult patients with RA treated with immunomodulating drugs.
Kapetanovic MC; Roseman C; Jönsson G; Truedsson L
Clin Rheumatol; 2011 Dec; 30(12):1555-61. PubMed ID: 21956234
[TBL] [Abstract][Full Text] [Related]
25. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study.
Hung CC; Chen MY; Hsieh SM; Hsiao CF; Sheng WH; Chang SC
Vaccine; 2004 May; 22(15-16):2006-12. PubMed ID: 15121313
[TBL] [Abstract][Full Text] [Related]
26. Isolating polysaccharide IgG pneumococcal antibody responses by pre-adsorption of conjugate vaccine serotypes: A modified approach for the conjugate vaccine era.
Mohamed OE; Williams L; Wong GK; Hayes M; Townsend K; Harding S; Huissoon AP
J Immunol Methods; 2020 Nov; 486():112846. PubMed ID: 32882318
[TBL] [Abstract][Full Text] [Related]
27. Pneumococcal conjugate vaccine-elicited antibody persistence and immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously vaccinated with 4 doses of either 7-valent or 13-valent pneumococcal conjugate vaccine.
Quinet B; Laudat F; Gurtman A; Patterson S; Sidhu M; Gruber WC; Scott DA
Pediatr Infect Dis J; 2014 Oct; 33(10):1065-76. PubMed ID: 25093973
[TBL] [Abstract][Full Text] [Related]
28. Pneumococcal responses are similar in Papua New Guinean children aged 3-5 years vaccinated in infancy with pneumococcal polysaccharide vaccine with or without prior pneumococcal conjugate vaccine, or without pneumococcal vaccination.
van den Biggelaar AHJ; Richmond PC; Fuery A; Anderson D; Opa C; Saleu G; Lai M; Francis JP; Alpers MP; Pomat WS; Lehmann D
PLoS One; 2017; 12(10):e0185877. PubMed ID: 29028802
[TBL] [Abstract][Full Text] [Related]
29. Immunogenicity of a combined schedule of 7-valent pneumococcal conjugate vaccine followed by a 23-valent polysaccharide vaccine in adult recipients of heart or lung transplants.
Gattringer R; Winkler H; Roedler S; Jaksch P; Herkner H; Burgmann H
Transpl Infect Dis; 2011 Oct; 13(5):540-4. PubMed ID: 21489090
[TBL] [Abstract][Full Text] [Related]
30. Immunogenicity of a 7-valent pneumococcal conjugate vaccine (PCV7) and impact on carriage in Venezuelan children at risk of invasive pneumococcal diseases.
Rivera-Olivero IA; Del Nogal B; Fuentes M; Cortez R; Bogaert D; Hermans PW; Waard JH
Vaccine; 2014 Jun; 32(31):4006-11. PubMed ID: 24837505
[TBL] [Abstract][Full Text] [Related]
31. Safety and immunogenicity of booster immunization with 7-valent pneumococcal conjugate vaccine in children with idiopathic nephrotic syndrome.
Liakou CD; Askiti V; Mitsioni A; Stefanidis CJ; Theodoridou MC; Spoulou VI
Vaccine; 2014 Mar; 32(12):1394-7. PubMed ID: 24486348
[TBL] [Abstract][Full Text] [Related]
32. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
Jackson LA; Gurtman A; van Cleeff M; Jansen KU; Jayawardene D; Devlin C; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
Vaccine; 2013 Aug; 31(35):3577-84. PubMed ID: 23688526
[TBL] [Abstract][Full Text] [Related]
33. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
Jackson LA; Gurtman A; Rice K; Pauksens K; Greenberg RN; Jones TR; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
Vaccine; 2013 Aug; 31(35):3585-93. PubMed ID: 23688527
[TBL] [Abstract][Full Text] [Related]
34. Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial.
Søgaard OS; Lohse N; Harboe ZB; Offersen R; Bukh AR; Davis HL; Schønheyder HC; Østergaard L
Clin Infect Dis; 2010 Jul; 51(1):42-50. PubMed ID: 20504165
[TBL] [Abstract][Full Text] [Related]
35. Cellular CD4 T cell responses to the diphtheria-derived carrier protein of conjugated pneumococcal vaccine and antibody response to pneumococcal vaccination in HIV-infected adults.
Rabian C; Tschöpe I; Lesprit P; Katlama C; Molina JM; Meynard JL; Delfraissy JF; Chêne G; Lévy Y;
Clin Infect Dis; 2010 Apr; 50(8):1174-83. PubMed ID: 20210645
[TBL] [Abstract][Full Text] [Related]
36. Time interval of revaccination with 23-valent pneumococcal polysaccharide vaccine more than 5 years does not affect the immunogenicity and safety in the Japanese elderly.
Kawakami K; Kishino H; Kanazu S; Takahashi K; Iino T; Sawata M; Musey L
Hum Vaccin Immunother; 2018; 14(8):1931-1938. PubMed ID: 29580133
[TBL] [Abstract][Full Text] [Related]
37. [Immunogenicity and safety of revaccination of 23-valent pneumococcal polysaccharide vaccine in people aged 60 years and above].
Ma QL; Zhang M; Liu LJ; Zhou Y; Yuan W; Yang M; Liu SX; Luo LY; Chen HP; Xiao YH; Qi Q; Yang XM
Zhonghua Liu Xing Bing Xue Za Zhi; 2023 Jul; 44(7):1119-1125. PubMed ID: 37482716
[No Abstract] [Full Text] [Related]
38. Improved plasmablast response after repeated pneumococcal revaccinations following primary immunization with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia.
Kättström M; Uggla B; Tina E; Kimby E; Norén T; Athlin S
Vaccine; 2023 May; 41(19):3128-3136. PubMed ID: 37061372
[TBL] [Abstract][Full Text] [Related]
39. 13-Valent pneumococcal conjugate vaccine (PCV13) in children partially immunized with 7-valent pneumococcal conjugate vaccine (PCV7): a phase 3, open-label trial.
Silfverdal SA; Flodmark CE; Rombo L; Tansey SP; Sidhu M; Trammel J; Emini EA; Gruber WC; Scott DA; Gurtman A;
Vaccine; 2013 Feb; 31(9):1284-92. PubMed ID: 23306363
[TBL] [Abstract][Full Text] [Related]
40. Pneumococcal polysaccharide 23-valent vaccine: long-term persistence of circulating antibody and immunogenicity and safety after revaccination in adults.
Grabenstein JD; Manoff SB
Vaccine; 2012 Jun; 30(30):4435-44. PubMed ID: 22542818
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
